Browse CHST3

Summary
SymbolCHST3
Namecarbohydrate (chondroitin 6) sulfotransferase 3
Aliases C6ST1; HSD; C6ST-1; GST-0; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosa ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus membrane Single-pass type II membrane protein
Domain PF00685 Sulfotransferase domain
Function

Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of the N-acetylgalactosamine (GalNAc) residue of chondroitin. Chondroitin sulfate constitutes the predominant proteoglycan present in cartilage and is distributed on the surfaces of many cells and extracellular matrices. Can also sulfate Gal residues of keratan sulfate, another glycosaminoglycan, and the Gal residues in sialyl N-acetyllactosamine (sialyl LacNAc) oligosaccharides. May play a role in the maintenance of naive T-lymphocytes in the spleen.

> Gene Ontology
 
Biological Process GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006029 proteoglycan metabolic process
GO:0006790 sulfur compound metabolic process
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0030166 proteoglycan biosynthetic process
GO:0030203 glycosaminoglycan metabolic process
GO:0030204 chondroitin sulfate metabolic process
GO:0030206 chondroitin sulfate biosynthetic process
GO:0044272 sulfur compound biosynthetic process
GO:0050650 chondroitin sulfate proteoglycan biosynthetic process
GO:0050654 chondroitin sulfate proteoglycan metabolic process
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0001517 N-acetylglucosamine 6-O-sulfotransferase activity
GO:0008146 sulfotransferase activity
GO:0008459 chondroitin 6-sulfotransferase activity
GO:0016782 transferase activity, transferring sulfur-containing groups
GO:0034481 chondroitin sulfotransferase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00532 Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate
Reactome R-HSA-2022870: Chondroitin sulfate biosynthesis
R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolCHST3
Namecarbohydrate (chondroitin 6) sulfotransferase 3
Aliases C6ST1; HSD; C6ST-1; GST-0; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosa ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CHST3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCHST3
Namecarbohydrate (chondroitin 6) sulfotransferase 3
Aliases C6ST1; HSD; C6ST-1; GST-0; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosa ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CHST3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCHST3
Namecarbohydrate (chondroitin 6) sulfotransferase 3
Aliases C6ST1; HSD; C6ST-1; GST-0; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosa ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CHST3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3710.144
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0020.999
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6460.516
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2080.613
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1030.949
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3420.868
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2060.628
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.070.961
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3490.829
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7940.528
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3280.444
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6524.1e-06
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CHST3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCHST3
Namecarbohydrate (chondroitin 6) sulfotransferase 3
Aliases C6ST1; HSD; C6ST-1; GST-0; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosa ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CHST3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCHST3
Namecarbohydrate (chondroitin 6) sulfotransferase 3
Aliases C6ST1; HSD; C6ST-1; GST-0; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosa ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CHST3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CHST3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCHST3
Namecarbohydrate (chondroitin 6) sulfotransferase 3
Aliases C6ST1; HSD; C6ST-1; GST-0; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosa ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CHST3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCHST3
Namecarbohydrate (chondroitin 6) sulfotransferase 3
Aliases C6ST1; HSD; C6ST-1; GST-0; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosa ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CHST3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCHST3
Namecarbohydrate (chondroitin 6) sulfotransferase 3
Aliases C6ST1; HSD; C6ST-1; GST-0; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosa ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CHST3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCHST3
Namecarbohydrate (chondroitin 6) sulfotransferase 3
Aliases C6ST1; HSD; C6ST-1; GST-0; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosa ......
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CHST3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.